Investment
Features
FeesSafety
Academy
More
Pluang+

Compare KE Holdings Inc (BEKE) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

KE Holdings IncTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

KE Holdings Inc vs Inovio Pharmaceuticals Inc — how do they compare? KE Holdings Inc trades at $17.34 (market cap $18.92B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: KE Holdings Inc is far larger — about 240.9× Inovio Pharmaceuticals Inc's market cap, and KE Holdings Inc pays a 1.63% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

BEKEINO
Market Cap
$18.92B$78.55M
Sector
TechnologyHealth
52-Week High
$20.36$2.87
52-Week Low
$14.26$0.66
Enterprise Value
$14.66B$49.56M
Dividend Yield
1.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

KE Holdings Inc

BEKE trades at $17.23, down 2.38% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 results, beating EPS estimates with $0.20 vs. $0.14 expected, while revenue declined to $90.1B in 2026 from $94.6B in 2025. Analyst sentiment remains overwhelmingly positive with 91.67% buy ratings. Cash flow trends show improvement with operating cash flow turning positive in 2026 at $2.1B.

The outlook appears favorable with improving profitability and strong analyst support, though risks include revenue contraction and China's property market exposure. The stock's current valuation at P/E 38.53 appears elevated but is supported by earnings growth potential and market leadership position in Chinese housing services.

Inovio Pharmaceuticals Inc

INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.

The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.

Returns comparison

Trailing returns across standard periods

About KE Holdings Inc

KE Holdings (Beike) is China’s leading platform for housing transactions and services. It operates the Lianjia brand and uses data-driven technology to facilitate home sales, rentals, and home renovation services.

Read more on BEKE

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO